Physician profile
John Herbert Sumners
NPI 1477502607
$733.13
in general payments reported to CMS, 2019-2025
15 companies · $68.24 in 2025
The $68.24 reported for 2025 was less than what a typical Adolescent Medicine (Pediatrics) provider received nationally (typical 2025 total: $99.31).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $214 · 2020: $131 · 2021: $96.12 · 2022: $33.90 · 2023: $33.94 · 2024: $156 · 2025: $68.24.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $257.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cordis US Corp. | $119.99 | 2024 | Selution Slrpta |
| Sanofi Pasteur INC. | $86.00 | 2021-2025 | |
| Ironshore Pharmaceuticals INC. | $65.94 | 2019-2023 | Jornay Pm |
| Adlon Therapeutics L.P. | $65.29 | 2019-2020 | |
| Glaxosmithkline, LLC. | $63.18 | 2019-2022 | |
| Tris Pharma INC | $62.44 | 2019-2025 | Dyanavel Xr |
| Genentech USA, INC. | $49.87 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.23 | 2020-2021 | |
| Pfizer INC. | $43.52 | 2019-2021 | |
| Shire North American Group INC | $42.55 | 2019 | |
| Corium, LLC | $22.81 | 2021-2024 | Azstarys |
| Sobi, INC | $17.58 | 2020 | |
| Supernus Pharmaceuticals, INC. | $16.80 | 2025 | Qelbree |
| Merck Sharp & Dohme LLC | $15.48 | 2021 | |
| Vertical Pharmaceuticals, LLC | $15.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Sumners listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.